Pharmaceutical pipeline for NASH treatment (nucleic acid medicine)
Introduction of compounds expected to be developed as new NASH treatments.
At Renac Therapeutics, we handle "Pharmaceutical Pipeline NASH Therapeutics (Nucleic Acid Medicines)." Using our proprietary technology, Hetero Double-Stranded Nucleic Acid (HDO) technology, we have discovered compounds that inhibit the expression of the NASH-related gene IHH. These compounds are expected to improve the NAFLD activity score in NASH animal models by inhibiting IHH expression, paving the way for the development of a novel NASH therapeutic. [Features] - Effectively inhibits the expression of the NASH-related gene IHH. - Also suppresses the expression of fibrosis marker genes such as COL1A1, CTGF, and TIMP1, suggesting potential as a fibrosis treatment. *For more details, please refer to the PDF document or feel free to contact us.
- Company：レナセラピューティクス
- Price：Other
